Welcome to La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is dedicated to the development of treatments that significantly improve outcomes in patients with life-threatening diseases.  Our current efforts focus on the clinical evaluation of GCS-100, a galectin antagonist, as a treatment for chronic organ disease and LJPC-501, an antagonist of the renin-angiotensin pathway, as a treatment for hepatorenal syndrome, a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure.  In addition, our experienced team of scientists are expanding our pipeline by developing innovative new therapies to treat diseases of the liver and lung as well as cancer.


Current Clinical Studies:  A Phase 2 Study of Weekly Doses of GCS-100 in Patients with Chronic Kidney Disease


Phase 2 Clinical Study Protocol: 4002 Study Protocol

Phase 2 Clinical Study Statistical Analysis Plan: 4002 SAP

Phase 2 Extenstion Clinical Study Protocol: 4003 Study Protocol


Phase 2 results conference call and webcast

Tuesday, March 11, 2014

8:30 AM Eastern Time/5:30 AM Pacific Time

You can participate on the call by either dialing (877) 359-9508 pin: 11631205 or clicking here for the webcast.


26th Annual ROTH Conference 2014

3/10/2014 2:30 PM (PT)

Webcast Link: Roth Conference 2014

Presentation Slides: ROTH March 2014


BIO CEO & Investor Conference 2014

Webcast Link: Bio CEO & Investor Webcast

Presentation Slides: BioCEO Feb 2014


ASN Poster  : Poster November 7, 2013


BIO Investor Forum

Corporate Presentation: BIO Investor Forum Presentation October 8, 2013